ZULRESSO Drug Patent Profile

When do Zulresso patents expire, and when can generic versions of Zulresso launch?

Zulresso is a drug marketed by Sage Therap Supernus and is included in one NDA. There are eight patents protecting this drug.

This drug has one hundred and thirty-two patent family members in thirty-two countries.

The generic ingredient in ZULRESSO is brexanolone. Additional details are available on the brexanolone profile page.

DrugPatentWatch^® Generic Entry Outlook for Zulresso

Zulresso was eligible for patent challenges on June 17, 2023.

By analyzing the patents and regulatory protections it appears that the earliest date for generic entry will be March 13, 2029. This may change due to patent challenges or generic licensing.

There have been six patent litigation cases involving the patents protecting this drug, indicating strong interest in generic launch. Recent data indicate that 63% of patent challenges are decided in favor of the generic patent challenger and that 54% of successful patent challengers promptly launch generic drugs.

Indicators of Generic Entry

Summary for ZULRESSO

International Patents:	132
US Patents:	8
Applicants:	1
NDAs:	1
Raw Ingredient (Bulk) Api Vendors:	56
Clinical Trials:	8
Drug Prices:	Drug price information for ZULRESSO
Patent Litigation and PTAB cases:	See patent lawsuits and PTAB cases for ZULRESSO
What excipients (inactive ingredients) are in ZULRESSO?	ZULRESSO excipients list
DailyMed Link:	ZULRESSO at DailyMed

See drug prices for ZULRESSO

DrugPatentWatch^® Estimated Loss of Exclusivity (LOE) Date for ZULRESSO

NDA:

211371

Dosage:

SOLUTION;INTRAVENOUS

^*The generic entry opportunity date is the latter of the last compound-claiming patent and the last regulatory exclusivity protection. Many factors can influence early or later generic entry. This date is provided as a rough estimate of generic entry potential and should not be used as an independent source.

Recent Clinical Trials for ZULRESSO

Identify potential brand extensions & 505(b)(2) entrants

Sponsor	Phase
RTI International	PHASE2
Pharmacotherapies for Alcohol and Substance Use Disorders Alliance	PHASE2
United States Department of Defense	PHASE2

See all ZULRESSO clinical trials

US Patents and Regulatory Information for ZULRESSO

ZULRESSO is protected by eight US patents.

Generics may enter earlier, or later, based on new patent filings, patent extensions, patent invalidation, early generic licensing, generic entry preferences, and other factors.

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	TE	Type	RLD	RS	Patent No.	Patent Expiration	Product	Substance	Delist Req.	Exclusivity Expiration
Sage Therap Supernus	ZULRESSO	brexanolone	SOLUTION;INTRAVENOUS	211371-001	Jun 17, 2019		DISCN	Yes	No
Sage Therap Supernus	ZULRESSO	brexanolone	SOLUTION;INTRAVENOUS	211371-001	Jun 17, 2019		DISCN	Yes	No			Y
Sage Therap Supernus	ZULRESSO	brexanolone	SOLUTION;INTRAVENOUS	211371-001	Jun 17, 2019		DISCN	Yes	No			Y

International Patents for ZULRESSO

When does loss-of-exclusivity occur for ZULRESSO?

Based on analysis by DrugPatentWatch, the following patents block generic entry in the countries listed below:

Australia

Brazil

Canada

China

Eurasian Patent Organization

European Patent Office

Hong Kong

Israel

Japan

Mexico

New Zealand

South Korea

Generics may enter earlier, or later, based on new patent filings, patent extensions, patent invalidation, early generic licensing, generic entry preferences, and other factors.

See the table below for additional patents covering ZULRESSO around the world.

Country	Patent Number	Title	Estimated Expiration
Australia	2009241858
Brazil	PI0905080
Canada	2702603

Zulresso Market Dynamics and Financial Trajectory: Brexanolone Sales, Commercial Outlook, and Exclusivity

Last updated: August 6, 2026

Zulresso, the brand name for brexanolone, was FDA-approved in 2019 as the first drug specifically indicated for postpartum depression. Its commercial trajectory has been constrained by a 60-hour continuous intravenous infusion, mandatory monitoring under a Risk Evaluation and Mitigation Strategy, hospital administration, and a high treatment cost. The product generated limited revenue relative to the size of the postpartum depression market and was eclipsed commercially by Sage Therapeutics' oral product, Zurzuvae.

What is Zulresso and what market does it address?

Zulresso is an intravenous formulation of brexanolone, an allopregnanolone analogue that modulates gamma-aminobutyric acid type A receptors. The FDA approved it for the treatment of postpartum depression in adults.[1]

Postpartum depression affects a substantial share of women after childbirth, but only a fraction of patients receive a specialized pharmaceutical intervention. The relevant commercial market is limited by:

• Underdiagnosis and undertreatment
• Short treatment windows after childbirth
• Insurance and hospital reimbursement constraints
• Patient reluctance to undergo inpatient infusion
• Competition from selective serotonin reuptake inhibitors and psychotherapy
• The availability of oral zuranolone, approved in 2023

Zulresso's pharmacologic differentiation is rapid improvement in depressive symptoms. Its commercial weakness is delivery. Patients must receive a continuous intravenous infusion over 60 hours in a certified healthcare setting, with monitoring for excessive sedation, sudden loss of consciousness, and oxygen desaturation.[1]

When did Zulresso launch and how did sales develop?

Zulresso launched in the United States in 2019 through Sage Therapeutics. The product's wholesale acquisition cost was approximately $34,000 for the drug alone, before hospital, administration, and monitoring costs.[2] The all-in treatment cost could be materially higher.

Public disclosures indicate that Zulresso sales remained modest during its commercial life. Sage's reporting categorized Zulresso revenue as net product sales. The following trajectory is based on company annual reports and investor disclosures:

Year	Approximate Zulresso net product sales	Commercial interpretation
2019	Low single-digit millions	Partial-year launch
2020	Approximately $6 million	COVID-19 disrupted hospital-based treatment
2021	Approximately $8 million to $9 million	Recovery remained limited
2022	Approximately $14 million to $15 million	Higher utilization, but small absolute base
2023	Approximately $13 million to $14 million	Oral competition and persistent administration barriers

The product never approached the revenue scale initially associated with a first-in-class therapy for a prevalent psychiatric condition. COVID-19 reduced elective hospital utilization shortly after launch, but the larger structural issue was the treatment model. Hospitals needed trained staff, infusion capacity, monitoring procedures, and reimbursement certainty for a non-emergency psychiatric treatment.

Why did Zulresso underperform commercially?

Zulresso's underperformance resulted from a mismatch between clinical benefit and treatment logistics.

The 60-hour infusion limited adoption

Zulresso required patients to remain in a healthcare facility for approximately two and a half days. The infusion created operational burdens for hospitals and substantial disruption for new mothers caring for infants.

A drug that improves symptoms rapidly has strong clinical value in severe postpartum depression. The benefit was difficult to monetize when access required inpatient or hospital-based administration.

The treatment cost exceeded the drug price

The approximately $34,000 wholesale drug price excluded facility fees, nursing, monitoring, and other administration costs. Payers could evaluate Zulresso as a high-cost treatment episode rather than as an outpatient prescription.

Reimbursement complexity also affected hospital willingness to offer the product. Hospitals had to carry operational and financial risk while treating a relatively low number of eligible patients.

The market was fragmented across treatment providers

Postpartum depression treatment is delivered through obstetricians, primary-care physicians, psychiatrists, maternal-fetal medicine specialists, and hospital systems. Zulresso required coordination across these providers and a referral pathway into an approved infusion setting.

Oral therapies created a lower-friction alternative

Before Zurzuvae, standard antidepressants remained the main pharmaceutical treatment option. After the FDA approved Zurzuvae in August 2023, clinicians gained an oral neuroactive steroid treatment that could be prescribed without a 60-hour infusion.[3]

This materially weakened Zulresso's strategic position. The two products share a mechanism-related commercial narrative, but Zurzuvae has a substantially more practical delivery model.

How does Zulresso compare with Zurzuvae?

Attribute	Zulresso	Zurzuvae
Active ingredient	Brexanolone	Zuranolone
Administration	Continuous intravenous infusion	Oral capsule
Treatment duration	60 hours	14 days
FDA approval	2019	2023
Indication	Postpartum depression in adults	Postpartum depression in adults
Monitoring burden	Hospital-based monitoring under REMS	Outpatient oral use, subject to labeling requirements
Primary commercial sponsor	Sage Therapeutics	Sage Therapeutics and Biogen commercialization partnership
Main advantage	Rapid pharmacologic effect with controlled administration	Convenience and lower treatment-site burden
Main commercial limitation	Infusion logistics and cost	Short-course adherence, reimbursement, and market education

Zulresso remains differentiated by its rapid onset and controlled inpatient delivery. Zurzuvae has the stronger commercial design because it is easier to prescribe, dispense, and administer.

The launch of Zurzuvae also redirected Sage's commercial resources. The company's investment case shifted from building a hospital infusion market to scaling a branded oral neuropsychiatric product.

What is the FDA regulatory status of Zulresso?

The FDA approved Zulresso under the traditional approval pathway in March 2019.[1] Its approval established brexanolone as a treatment for postpartum depression in adults.

Important regulatory characteristics include:

• A boxed warning for excessive sedation and sudden loss of consciousness
• Continuous monitoring during infusion
• Administration only in certified healthcare facilities under the Zulresso REMS
• Restrictions related to patient alertness and the ability to care for an infant during treatment
• Intravenous administration over 60 hours

The REMS structure was central to the product's safety profile but increased commercial friction. Every additional requirement between prescription and administration reduces the number of centers able to offer treatment and increases payer and provider coordination costs.

What patents protect Zulresso and when could generic entry occur?

Zulresso is a small-molecule drug, not a biologic. A future competitor would therefore generally use the abbreviated new drug application pathway rather than a biosimilar pathway.

Public patent databases and FDA Orange Book materials identify patent protection associated with brexanolone and its use or formulation. The principal commercial protection has been linked to patents covering neuroactive steroid compositions, pharmaceutical formulations, and therapeutic use. Patent expiry analysis must distinguish between:

• Basic compound or composition claims
• Formulation claims
• Method-of-use claims
• Pediatric exclusivity, if granted
• Patent-term adjustment or extension
• Orange Book listing status
• Any settlement limiting an approved ANDA launch date

The core commercial patent estate does not eliminate the delivery and reimbursement problems that affected Zulresso. A generic brexanolone entrant could face manufacturing and clinical-use barriers, but the small market may reduce the economic incentive to challenge every listed patent.

No biosimilar risk applies because brexanolone is a chemically synthesized small molecule. The relevant threat is generic competition through an ANDA, including a potential Paragraph IV certification against listed patents.

What generic entry risks exist for Zulresso?

Generic entry risk is moderate from a legal perspective but potentially limited from a commercial perspective.

A generic applicant would need to address:

1. Sterile injectable manufacturing requirements
2. The 60-hour infusion regimen
3. Drug-device and administration compatibility
4. Stability and container-closure specifications
5. REMS and distribution requirements
6. Limited prescription volume
7. Hospital procurement economics
8. Any Orange Book-listed formulation or use patents

The small addressable market may discourage early generic development. Conversely, a low-cost generic could make hospital treatment more financially viable if payers reimburse the infusion episode adequately.

What is the Orange Book status of Zulresso?

Zulresso is listed in FDA drug-product databases as an approved prescription drug under NDA 211371. The Orange Book is the relevant source for current patent listings, exclusivity codes, and any approved generic applications.[4]

FDA approval does not mean that all commercial protection remains active. The key distinction is between:

• FDA regulatory exclusivity, which is time-limited from approval; and
• Patent protection, which depends on individual claims and expiration calculations.

Zulresso's five-year new chemical entity exclusivity from the 2019 approval would have ended in 2024, subject to the precise FDA exclusivity date. The product's residual protection therefore depends primarily on active patents and the economic attractiveness of an ANDA launch.

Which companies are challenging or competing with Zulresso?

The principal competitive pressure has come from alternative treatments rather than from a disclosed generic litigation campaign.

Sage Therapeutics and Biogen

Sage developed Zulresso and later partnered with Biogen on zuranolone. Biogen's commercial involvement increased the strategic focus on Zurzuvae, which had a more scalable distribution model.[5]

Traditional antidepressant manufacturers

Generic sertraline, fluoxetine, escitalopram, and other antidepressants compete with Zulresso on cost, familiarity, and outpatient availability. These products do not share Zulresso's rapid-onset profile, but they have established reimbursement and prescribing pathways.

Other neuroactive steroid programs

Zuranolone is the most important direct product-level competitor because it targets the same disease area and offers oral dosing. Other companies developing postpartum depression therapies could compete through oral agents, digital care pathways, or long-acting formulations.

What patent litigation and settlement activity affects Zulresso?

There is no major publicly established Paragraph IV litigation campaign that has become a defining commercial event for Zulresso. The absence of prominent litigation is consistent with the product's limited sales and difficult administration model.

The commercial risk is therefore less dependent on an imminent court judgment than on the combination of:

• Expiration of regulatory exclusivity
• Remaining Orange Book patent terms
• Low prescription volume
• Physician migration to oral therapy
• Hospital reluctance to maintain infusion capability
• Payer preference for lower-cost alternatives

A generic applicant could still create an ANDA litigation event if it concludes that the market supports entry. The business case would depend on whether a lower drug price expands treatment volume enough to offset sterile manufacturing and distribution costs.

How strong is the Zulresso patent estate?

Zulresso's patent estate is commercially meaningful but not sufficient to support a large franchise without operational adoption.

Patent-strength assessment should consider four factors:

Factor	Assessment
Composition protection	Potentially stronger if claims cover the active neuroactive steroid broadly
Formulation protection	Relevant because Zulresso is a specialized sterile injectable
Method-of-use protection	Narrower value because postpartum depression treatment can be approached through alternative drugs
Commercial durability	Limited by small sales and oral competition

A patent can delay generic entry while failing to create a durable commercial moat. Zulresso illustrates that distinction. Its delivery system, REMS requirements, and market access barriers had a greater effect on sales than patent protection alone.

What is Zulresso's revenue exposure for Sage Therapeutics?

Zulresso became a small component of Sage's revenue base. Its sales were not sufficient to support the company's broader valuation or commercial infrastructure. The strategic value of the product was higher than its direct revenue because it established Sage's regulatory and clinical position in postpartum depression.

The financial trajectory shifted after Zurzuvae's approval. Investors began evaluating Sage on:

• Zurzuvae prescription growth
• Commercial execution with Biogen
• Payer coverage
• Net price after rebates
• Market share against generic antidepressants
• Expansion into major depressive disorder
• Cash burn and operating leverage
• Dependence on a small number of products

Zulresso's financial contribution was therefore mainly legacy revenue and clinical validation rather than a growth engine.

What generic launch scenarios exist for Zulresso?

Scenario 1: No near-term generic launch

This is the most commercially logical scenario if demand remains low. A potential entrant may avoid the cost of sterile manufacturing, regulatory work, and hospital distribution for a product with limited annual sales.

Scenario 2: Paragraph IV challenge with an early launch attempt

A generic company could challenge listed patents if it believes a lower price would expand utilization or if the patent estate is narrow. The likely litigation would focus on formulation, use, or patent validity.

Scenario 3: Post-patent hospital generic

A generic could enter after relevant patent expiry and compete primarily through hospital purchasing contracts. The product would need to match infusion quality, reliability, and supply continuity.

Scenario 4: Commercial withdrawal before meaningful generic competition

If utilization declines materially, the branded product could become commercially marginal before a generic is approved. In that case, the principal market event would be discontinuation or restricted distribution rather than a conventional generic erosion curve.

What is the long-term commercial outlook for Zulresso?

Zulresso has limited growth potential as a standalone branded product. Its clinical differentiation remains rapid action, but the 60-hour infusion, REMS, hospital cost, and competition from oral zuranolone restrict adoption.

The product could retain a niche role for patients needing rapid intervention, patients unable to tolerate oral therapy, or institutions with established infusion programs. That niche is unlikely to generate revenue comparable with a scalable outpatient product.

The central commercial question is not whether brexanolone works. It is whether healthcare systems will fund and operationalize a 60-hour infusion when an oral neuroactive steroid is available. Current market structure favors the oral product.

Key Takeaways

• Zulresso was FDA-approved in 2019 as the first drug specifically indicated for postpartum depression.
• Its 60-hour intravenous infusion and REMS requirements limited patient access and hospital adoption.
• The approximately $34,000 drug price excluded substantial administration and monitoring costs.
• Annual sales remained modest, generally in the single-digit to mid-teens millions of dollars.
• FDA regulatory exclusivity from the 2019 approval has expired or reached its end period, leaving patent status as the main remaining legal protection.
• Zulresso faces generic rather than biosimilar risk because brexanolone is a small molecule.
• No major publicly established Paragraph IV litigation has defined the product's market.
• Zurzuvae is the principal direct competitor and has a more scalable oral delivery model.
• Zulresso's patent estate may delay competition but cannot resolve its reimbursement and administration constraints.
• The product's long-term value is more likely to be niche clinical utility than material revenue growth.

FAQs About Zulresso Market and Patent Risk

Is Zulresso still commercially available in the United States?

Zulresso's availability depends on the sponsor's commercial strategy, certified treatment centers, and current distribution arrangements. Its market presence has remained limited relative to oral postpartum depression treatments.

Can a pharmacy dispense Zulresso for home infusion?

The FDA-approved treatment model requires administration in a certified healthcare setting with continuous monitoring. Standard retail-pharmacy dispensing is not the ordinary pathway.

Is brexanolone covered by Medicare or Medicaid?

Coverage varies by payer, state, medical-benefit classification, prior authorization rules, and site-of-care policy. Hospital administration and monitoring costs can be as important as the drug acquisition price.

Does Zulresso have orphan-drug exclusivity?

Zulresso was approved for postpartum depression, a condition affecting a large population. Its principal regulatory protection was new chemical entity exclusivity rather than a conventional orphan-drug strategy.

Could a generic company make an oral version of brexanolone?

An oral brexanolone product would not be an ordinary generic version of Zulresso because it would differ in dosage form, route of administration, and potentially clinical requirements. It would likely require a separate regulatory strategy.

References

1. U.S. Food and Drug Administration. (2019). FDA approves first treatment for postpartum depression. https://www.fda.gov/news-events/press-announcements/fda-approves-first-treatment-post-partum-depression

2. Sage Therapeutics, Inc. (2019). Zulresso prescribing information. U.S. Food and Drug Administration.

3. U.S. Food and Drug Administration. (2023). FDA approves first oral treatment for postpartum depression. https://www.fda.gov/news-events/press-announcements/fda-approves-first-oral-treatment-postpartum-depression

4. U.S. Food and Drug Administration. (2024). Approved drug products with therapeutic equivalence evaluations, Orange Book. https://www.fda.gov/drugs/drug-approvals-and-databases/approved-drug-products-therapeutic-equivalence-evaluations-orange-book

5. Sage Therapeutics, Inc. (2024). Annual report pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934, Form 10-K. U.S. Securities and Exchange Commission.